ArticleFrontiers in pharmacology2026
Antidepressant-like effects of cannabidiol when combined with temozolomide in adult rats.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression. In this context, combination therapies, particularly cannabidiol with temozolomide exhibited additive or synergistic anti-tumor effects, capable of improving temozolomide's resistance over the course of treatment. Beyond its antitumoral properties and given the promising antidepressant-like profile of cannabidiol, we aimed at evaluating the pharmacological interaction of a combined therapy with cannabidiol and temozolomide as a potential novel antidepressant-like strategy, in comparison with temozolomide's combination with fluoxetine, the goal treatment standard for depressive-like symptomatology. To do so, adult male and female rats received (i.p.) temozolomide (25 mg/kg, 2 cycles, 5 days/cycle, 1 dose/day), cannabidiol (10 or 30 mg/kg, 3 doses within 24 h), fluoxetine (5-20 mg/kg, 3 doses within 24 h) alone and/or in combination. Antidepressant-like responses were scored under the stress of the forced-swim test. The results proved that all drugs induced antidepressant-like responses, although efficacy was related to sex and the dose administered. Moreover, the combination of fluoxetine with temozolomide was not different than the response induced by each drug separately. However, combining cannabidiol with temozolomide exhibited a sex-dependent antidepressant-like response solely observed in male rats, offering a potential therapeutic avenue to address depression in glioblastoma, where current antidepressants remain largely ineffective. Therefore, we propose that cannabidiol might be a good option to be administered in glioblastoma patients treated with temozolomide for improved affective-like responses, although not before its future validation in animal models of glioblastoma. Moreover, upcoming studies should center in personalizing the doses needed for this combinational approach to be also effective in females.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.